Revolution Medicines, Inc.
NASDAQ: RVMD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark A. Goldsmith
- Employees
- 616
- Headquarters
- Redwood City, United States
- IPO year
- 2020
- Market cap
- $34.7B
- Website
- https://www.revmed.com
Loading RVMD…
Loading profile data…Frequently asked questions about RVMD
What does Revolution Medicines, Inc. (RVMD) do?
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for var...
Where does RVMD trade?
Revolution Medicines, Inc. (RVMD) trades on the NASDAQ Global Select.
What sector is RVMD in?
Revolution Medicines, Inc. (RVMD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Revolution Medicines, Inc.?
Mark A. Goldsmith is the chief executive officer of Revolution Medicines, Inc. (RVMD).
Where is Revolution Medicines, Inc. headquartered?
Revolution Medicines, Inc. is headquartered in United States.
Does RVMD pay a dividend?
Revolution Medicines, Inc. (RVMD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RVMD go public?
Revolution Medicines, Inc. (RVMD) completed its initial public offering in 2020.